Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis
The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte's phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects. The literature search was conducted across two databases, PubMed, and Google Scholar. Eligible studies included clinical trials, observational studies, meta-analyses, systematic reviews, and narrative reviews. The objective of this article is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepines, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neurosurgical methods. Non-invasive methods, physical therapy, and psychotherapy (cognitive behavioral therapy, acceptance and commitmen…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meditation has also been shown to modulate the inflammatory response and reduce pain, possibly through neuroendocrine and immune system interactions [93].”
From Chronic Stress and Autoimmunity: The Role of HPA Axis and Cortisol Dysregulation (2025) · cites this paper as [93]
In the citing paper
“Meditation has also been shown to modulate the inflammatory response and reduce pain, possibly through neuroendocrine and immune system interactions [93].”
From Chronic Stress and Autoimmunity: The Role of HPA Axis and Cortisol Dysregulation (2025) · cites this paper as [93]
In the citing paper
“These findings are consistent with broader evidence supporting exercise-based therapies in autoimmune-related chronic pain conditions [93].”
From Chronic Stress and Autoimmunity: The Role of HPA Axis and Cortisol Dysregulation (2025) · cites this paper as [93]
Citations
Cites
2 retracted
Wang, H.-Y., Frankfurt, M., & Burns, L. H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001554 · Cited by 81
RetractedBoiko, D. I., Skrypnikov, A. M., Shkodina, A. D., Hasan, M. M., Ashraf, G. M., & Rahman, M. H. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-18384-4 · Cited by 76
Self-citationRetractedPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 2×
“A meta-analysis of double-blind studies found that topical or oral pharmacological therapy can effectively treat NP [90].”
Central sensitization: a generator of pain hypersensitivity by central neural plasticity
Latremoliere, A., & Woolf, C. J. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2009.06.012 · Cited by 3,913
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15767 · Cited by 3,163
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., Robertson, N., La Rocca, N., Uitdehaag, B., van der Mei, I., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520970841 · Cited by 2,653
Lefaucheur, J.-P., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., Filipović, S. R., Grefkes, C., Hasan, A., Hummel, F. C., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.11.002 · Cited by 2,382
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B. V., & Thompson, A. J. (2014) · Neurology · doi:10.1212/wnl.0000000000000768 · Cited by 1,223
Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy
Max, M. B., Lynch, S. A., Muir, J., Shoaf, S. E., Smoller, B., & Dubner, R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205073261904 · Cited by 1,117
Descending pain modulation and chronification of pain
Ossipov, M. H., Morimura, K., & Porreca, F. (2014) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0000000000000055 · Cited by 815
AAN-EFNS guidelines on trigeminal neuralgia management
Cruccu, G., Gronseth, G., Alksne, J., Argoff, C., Brainin, M., Burchiel, K., Nurmikko, T., & Zakrzewska, J. M. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02185.x · Cited by 726
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679 · cited 1×
“Although its full benefits for NP are still under investigation, data suggest that cannabis with a CBD:THC ratio of 1:1 or higher can reduce pain in patients with MS [113].”
Trigeminal neuralgia: New classification and diagnostic grading for practice and research
Cruccu, G., Finnerup, N. B., Jensen, T. S., Scholz, J., Sindou, M., Svensson, P., Treede, R.-D., Zakrzewska, J. M., & Nurmikko, T. (2016) · Neurology · doi:10.1212/wnl.0000000000002840 · Cited by 540
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500 · cited 2×
“A crossover trial by Svendsen et al. in 2004, using a total of 23 participants, showed that patients treated with a CBD/THC combination had a reduction in NP with the added benefit of improved sleep quality compared with participants given a placebo [72].”
Pain associated with multiple sclerosis: Systematic review and proposed classification
O’Connor, A. B., Schwid, S. R., Herrmann, D. N., Markman, J. D., & Dworkin, R. H. (2008) · Pain · doi:10.1016/j.pain.2007.08.024 · Cited by 498
Epidemiology of multiple sclerosis
Leray, E., Moreau, T., Fromont, A., & Edan, G. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.006 · Cited by 478 · cited 1×
“Multiple sclerosis (MS) is a chronic progressive immunological inflammatory disease that affects myelinated axons in the central nervous system (CNS) [1].”
Sindrup, S. H., Gram, L. F., Brøsen, K., Eshøj, O., & Mogensen, E. F. (1990) · Pain · doi:10.1016/0304-3959(90)91157-e · Cited by 463
A Brainstem-Spinal Cord Inhibitory Circuit for Mechanical Pain Modulation by GABA and Enkephalins
François, A., Low, S. A., Sypek, E. I., Christensen, A. J., Sotoudeh, C., Beier, K. T., Ramakrishnan, C., Ritola, K. D., Sharif-Naeini, R., Deisseroth, K., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.008 · Cited by 349
A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain
Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.12.010 · Cited by 327 · cited 1×
“A crossover trial study conducted in 2008 using cannabis cigarettes as a means of inhalation in patients with MS documented a reduction in NP compared with patients in the placebo group [70].”
Halabchi, F., Alizadeh, Z., Sahraian, M. A., & Abolhasani, M. (2017) · BMC Neurology · doi:10.1186/s12883-017-0960-9 · Cited by 324
Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain
Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013) · The Journal of Pain · doi:10.1016/j.jpain.2012.10.009 · Cited by 314 · cited 2×
“The NNT for the medium versus high dose was 25, showing that patients with MS can use inhaled cannabis to manage NP [71].”
Foley, P. L., Vesterinen, H. M., Laird, B. J., Sena, E. S., Colvin, L. A., Chandran, S., MacLeod, M. R., & Fallon, M. T. (2013) · Pain · doi:10.1016/j.pain.2012.12.002 · Cited by 310
Anticonvulsants in neuropathic pain: rationale and clinical evidence
Jensen, T. S. (2002) · European Journal of Pain · doi:10.1053/eujp.2001.0324 · Cited by 305
Hunter, Z., McCarthy, D. P., Yap, W. T., Harp, C. T., Getts, D. R., Shea, L. D., & Miller, S. D. (2014) · ACS Nano · doi:10.1021/nn405033r · Cited by 301
The prevalence of pain in multiple sclerosis: A multicenter cross-sectional study
Solaro, C., Brichetto, G., Amato, M. P., Cocco, E., Colombo, B., D’Aleo, G., Gasperini, C., Ghezzi, A., Martinelli, V., Milanese, C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000137047.85868.d6 · Cited by 291
Peripheral input and its importance for central sensitization
Baron, R., Hans, G., & Dickenson, A. H. (2013) · Annals of Neurology · doi:10.1002/ana.24017 · Cited by 280
Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews
Amatya, B., Khan, F., & Galea, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012732.pub2 · Cited by 271
Mori, F., Codecà, C., Kusayanagi, H., Monteleone, F., Buttari, F., Fiore, S., Bernardi, G., Koch, G., & Centonze, D. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2009.08.011 · Cited by 261
Persistent pain and uncomfortable sensations in persons with multiple sclerosis
Hadjimichael, O., Kerns, R. D., Rizzo, M. A., Cutter, G., & Vollmer, T. (2007) · Pain · doi:10.1016/j.pain.2006.07.015 · Cited by 257
Zhang, L., Berta, T., Xu, Z.-Z., Liu, T., Park, J. Y., & Ji, R.-R. (2011) · Pain · doi:10.1016/j.pain.2010.11.014 · Cited by 248
Hyman, N. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.707 · Cited by 248
Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia
Obermann, M., Yoon, M.-S., Ese, D., Maschke, M., Kaube, H., Diener, H.-C., & Katsarava, Z. (2007) · Neurology · doi:10.1212/01.wnl.0000269670.30045.6b · Cited by 231
Reappraising neuropathic pain in humans—how symptoms help disclose mechanisms
Truini, A., Garcia-Larrea, L., & Cruccu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.180 · Cited by 226
Pain in Patients With Multiple Sclerosis: A Population-Based Study
Svendsen, K. B., Jensen, T. S., Overvad, K., Hansen, H. J., Koch-Henriksen, N., & Bach, F. W. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1089 · Cited by 225
Wijma, A. J., van Wilgen, C. P., Meeus, M., & Nijs, J. (2016) · Physiotherapy Theory and Practice · doi:10.1080/09593985.2016.1194651 · Cited by 222
A mechanism-based classification of pain in multiple sclerosis
Truini, A., Barbanti, P., Pozzilli, C., & Cruccu, G. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6579-2 · Cited by 212
Gabapentin in the treatment of neuropathic pain
Bennett, M. I., & Simpson, K. H. (2004) · Palliative Medicine · doi:10.1191/0269216304pm845ra · Cited by 201
Pharmacological treatments of neuropathic pain: The latest recommendations
Attal, N. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2018.08.005 · Cited by 193
Trigeminal neuralgia and pain related to multiple sclerosis
Cruccu, G., Biasiotta, A., Di Rezze, S., Fiorelli, M., Galeotti, F., Innocenti, P., Mameli, S., Millefiorini, E., & Truini, A. (2009) · Pain · doi:10.1016/j.pain.2008.12.026 · Cited by 191
Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep
Piper, B. J., DeKeuster, R. M., Beals, M. L., Cobb, C. M., Burchman, C. A., Perkinson, L., Lynn, S. T., Nichols, S. D., & Abess, A. T. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699616 · Cited by 190
Harke, H., Gretenkort, P., Ladleif, H. U., Rahman, S., & Harke, O. (2001) · Anesthesia & Analgesia · doi:10.1097/00000539-200102000-00039 · Cited by 189
ROG, D., NURMIKKO, T., & YOUNG, C. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.013 · Cited by 187 · cited 1×
“In 2005, Rog et al. found that patients with MS who received oral THC experienced a significant reduction in pain compared with patients who had received a placebo [69].”
Central poststroke pain: A population-based study
Klit, H., Finnerup, N. B., Andersen, G., & Jensen, T. S. (2011) · Pain · doi:10.1016/j.pain.2010.12.030 · Cited by 184
Psychological Interventions for the Treatment of Chronic Pain in Adults
Driscoll, M. A., Edwards, R. R., Becker, W. C., Kaptchuk, T. J., & Kerns, R. D. (2021) · Psychological Science in the Public Interest · doi:10.1177/15291006211008157 · Cited by 176 · cited 2×
“At the same time, the study of multidisciplinary interventions that combine exercise and psychological interventions is an urgent issue [176].”
Mokhtari, T., Ren, Q., Li, N., Wang, F., Bi, Y., & Hu, L. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-0846-1 · Cited by 169
The molecular neurobiology of chronic pain–induced depression
Humo, M., Lu, H., & Yalcin, I. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03003-z · Cited by 163
Otero-Romero, S., Sastre-Garriga, J., Comi, G., Hartung, H.-P., Soelberg Sørensen, P., Thompson, A. J., Vermersch, P., Gold, R., & Montalban, X. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516643600 · Cited by 162
Di Stefano, G., Maarbjerg, S., & Truini, A. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-019-0969-0 · Cited by 161
Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial
Cutter, N. C., Scott, D. D., Johnson, J. C., & Whiteneck, G. (2000) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(00)90135-7 · Cited by 160
Microanatomy of the Central Myelin-Peripheral Myelin Transition Zone of the Trigeminal Nerve
Peker, S., Kurtkaya, Ö., Üzün, İ., & Pamir, M. N. (2006) · Neurosurgery · doi:10.1227/01.neu.0000223501.27220.69 · Cited by 160
Central Neuropathic Pain Syndromes
Watson, J. C., & Sandroni, P. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.01.017 · Cited by 158
Acceptance and commitment therapy: towards a unified model of behavior change
Hayes, S. C. (2019) · World Psychiatry · doi:10.1002/wps.20626 · Cited by 154 · cited 1×
“It is a widely used approach in treating NP associated with a range of disorders, including spinal cord injuries and diabetic peripheral neuropathy, among others [177, 178].”
Nielsen, S., Germanos, R., Weier, M., Pollard, J., Degenhardt, L., Hall, W., Buckley, N., & Farrell, M. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0814-x · Cited by 153
The IASP classification of chronic pain for ICD-11: chronic secondary headache or orofacial pain
Benoliel, R., Svensson, P., Evers, S., Wang, S.-J., Barke, A., Korwisi, B., Rief, W., Treede, R.-D., & Pain, T. I. T. F. T. C. O. C. (2019) · Pain · doi:10.1097/j.pain.0000000000001435 · Cited by 153
Multi-dimensionality of chronic pain of the oral cavity and face
Zakrzewska, J. M. (2013) · The Journal of Headache and Pain · doi:10.1186/1129-2377-14-37 · Cited by 140
Prefrontal tDCS Decreases Pain in Patients with Multiple Sclerosis
Ayache, S. S., Palm, U., Chalah, M. A., Al-Ani, T., Brignol, A., Abdellaoui, M., Dimitri, D., Sorel, M., Créange, A., & Lefaucheur, J.-P. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00147 · Cited by 138
Vrethem, M., Boivie, J., Arnqvist, H., Holmgren, H., Lindström, T., & Thorell, L.-H. (1997) · The Clinical Journal of Pain · doi:10.1097/00002508-199712000-00009 · Cited by 136
Applications and safety of gold nanoparticles as therapeutic devices in clinical trials
Yao, L., Bojic, D., & Liu, M. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.06.001 · Cited by 136
Pilot trial of low‐dose naltrexone and quality of life in multiple sclerosis
Cree, B., Kornyeyeva, E., & Goodin, D. S. (2010) · Annals of Neurology · doi:10.1002/ana.22006 · Cited by 135
Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review
Aiyer, R., Barkin, R. L., & Bhatia, A. (2016) · Pain Medicine · doi:10.1093/pm/pnw261 · Cited by 135
Cannabis-Based Medicines and Pain: A Review of Potential Synergistic and Entourage Effects
Anand, U., Pacchetti, B., Anand, P., & Sodergren, M. H. (2021) · Pain Management · doi:10.2217/pmt-2020-0110 · Cited by 133
Khan, N., & Smith, M. T. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0195-3 · Cited by 132
A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis
Truini, A., Prosperini, L., Calistri, V., Fiorelli, M., Pozzilli, C., Millefiorini, E., Frontoni, M., Cortese, A., Caramia, F., & Cruccu, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002720 · Cited by 130
Concomitant Persistent Pain in Classical Trigeminal Neuralgia – Evidence for Different Subtypes
Maarbjerg, S., Gozalov, A., Olesen, J., & Bendtsen, L. (2014) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12384 · Cited by 127
McCleane, G. J. (1999) · Anesthesia & Analgesia · doi:10.1213/00000539-199910000-00030 · Cited by 126
Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., Galloway, K., & Namaka, M. (2015) · Pain Medicine · doi:10.1111/pme.12569 · Cited by 124 · cited 1×
“A 2015 study with a sample size of 15 patients with MS and NP found that adding a synthetic oral THC mimic to gabapentin was effective in pain reduction and tolerated [115].”
Aborode, A. T., Pustake, M., Awuah, W. A., Alwerdani, M., Shah, P., Yarlagadda, R., Ahmad, S., Silva Correia, I. F., Chandra, A., Nansubuga, E. P., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7934442 · Cited by 124
Self-citationCoronado, R. A., Brintz, C. E., McKernan, L. C., Master, H., Motzny, N., Silva, F. M., Goyal, P. M., Wegener, S. T., & Archer, K. R. (2020) · PAIN Reports · doi:10.1097/pr9.0000000000000847 · Cited by 115
Neuropathic Pain and Deep Brain Stimulation
Pereira, E. A. C., & Aziz, T. Z. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0278-x · Cited by 110
McCleane, G. J. (1999) · Anesthesia & Analgesia · doi:10.1097/00000539-199910000-00030 · Cited by 107
Sachais, B. A. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500190056008 · Cited by 105
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
Karst, M., Wippermann, S., & Ahrens, J. (2010) · Drugs · doi:10.2165/11585260-000000000-00000 · Cited by 104
Pearson, R. M., Casey, L. M., Hughes, K. R., Wang, L. Z., North, M. G., Getts, D. R., Miller, S. D., & Shea, L. D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.015 · Cited by 99
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis
Gironi, M., Boneschi, F. M., Sacerdote, P., Solaro, C. M., Zaffaroni, M., Cavarretta, R., Moiola, L., Bucello, S., Radaelli, M., Pilato, V., et al. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508095828 · Cited by 98
Pain, pain, go away: antidepressants and pain management.
Sansone, R. A., & Sansone, L. A. (2008) · PubMed · Cited by 94
Palm, U., Chalah, M. A., Padberg, F., Al-ani, T., Abdellaoui, M., Sorel, M., Dimitri, D., Créange, A., Lefaucheur, J., & Ayache, S. S. (2016) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-150557 · Cited by 92
Reappraisal of Lhermitte’s sign in multiple sclerosis
Al-Araji, A. H., & Oger, J. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1177oa · Cited by 90
Descending facilitation: From basic science to the treatment of chronic pain
Zhuo, M. (2017) · Molecular Pain · doi:10.1177/1744806917699212 · Cited by 90
A comparison of baclofen and diazepam in the treatment of spasticity
Cartlidge, N. E. F., Hudgson, P., & Weightman, D. (1974) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(74)90137-3 · Cited by 88
Ma, T.-W., Yuen, A. S.-K., & Yang, Z. (2023) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000001096 · Cited by 88 · cited 1×
“A recent systematic review confirmed that ACT is efficacious and equivalent, if not better, than other existing active therapies for chronic pain [180].”
Non-invasive Brain Stimulation Therapy in Multiple Sclerosis: A Review of tDCS, rTMS and ECT Results
Palm, U., Ayache, S. S., Padberg, F., & Lefaucheur, J. (2014) · Brain stimulation · doi:10.1016/j.brs.2014.09.014 · Cited by 85
Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review
Liampas, A., Rekatsina, M., Vadalouca, A., Paladini, A., Varrassi, G., & Zis, P. (2020) · Pain and Therapy · doi:10.1007/s40122-020-00210-3 · Cited by 85
Sharafaddinzadeh, N., Moghtaderi, A., Kashipazha, D., Majdinasab, N., & Shalbafan, B. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510366857 · Cited by 83
Multiple Sclerosis-Related Central Pain Disorders
Nurmikko, T. J., Gupta, S., & Maclver, K. (2010) · Current Pain and Headache Reports · doi:10.1007/s11916-010-0108-8 · Cited by 83
Naranjo, C., del Reguero, L., Moratalla, G., Moreno, M. H., Valenzuela, M., & Failde, I. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1653760 · Cited by 83
Urits, I., Adamian, L., Fiocchi, J., Hoyt, D. J., Ernst, C. A., Kaye, A. D., & Viswanath, O. (2019) · Current Pain and Headache Reports · doi:10.1007/s11916-019-0800-2 · Cited by 82
Boiko, D. I., Shyrai, P. O., Mats, O. V., Karpik, Z. I., Rahman, M. H., Khan, A. A., Alanazi, A. M., & Skrypnikov, A. M. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.12.004 · Cited by 80
Self-citationLow-Dose Naltrexone for Chronic Pain: Update and Systemic Review
Kim, P. S., & Fishman, M. A. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-00898-0 · Cited by 78
A DOUBLE-BLIND TRIAL WITH BACLOFEN (LIORESAL®) AND DIAZEPAM IN SPASTICITY DUE TO MULTIPLE SCLEROSIS
From, A., & Heltberg, A. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1975.tb01366.x · Cited by 74
Murphy, K., Bethea, J. R., & Fischer, R. (2017) · Codon Publications eBooks · doi:10.15586/codon.multiplesclerosis.2017.ch4 · Cited by 72
Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression
Boiko, D. I., Shkodina, A. D., Hasan, M. M., Bardhan, M., Kazmi, S. K., Chopra, H., Bhutra, P., Baig, A. A., & Skrypnikov, A. M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03646-5 · Cited by 72
Self-citationHughes, C., Smyth, S., & Lowe-Strong, A. S. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509345916 · Cited by 71
Kaiman, S., Österberg, A., Sörensen, J., et al. (2002) · European Journal of Pain · doi:10.1053/eujp.2001.0307 · Cited by 70
Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment
Campos, R. M. P., Aguiar, A. F. L., Paes-Colli, Y., Trindade, P. M. P., Ferreira, B. K., Reis, R. A. D. M., & Sampaio, L. D. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.785176 · Cited by 69
Doolen, S., Iannitti, T., Donahue, R. R., Shaw, B. C., Grachen, C. M., & Taylor, B. K. (2017) · Pain · doi:10.1097/j.pain.0000000000001106 · Cited by 68
on behalf of the Neuropathic Pain Special Interest Group of the Italian Neurological Society, Solaro, C. M., Cella, M., Signori, A., Martinelli, V., Radaelli, M., Centonze, D., Sica, F., Grasso, M. G., Clemenzi, A., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8758-2 · Cited by 68
Reactive Astrocytes: Critical Players in the Development of Chronic Pain
Tang, J., Bair, M., & Descalzi, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.682056 · Cited by 67
Lamotrigine in the Management of Neuropathic Pain: A Review of the Literature
McCleane, G. J. (2000) · Clinical Journal of Pain · doi:10.1097/00002508-200012000-00008 · Cited by 66
Vollmer, T. L., Robinson, M. J., Risser, R. C., & Malcolm, S. K. (2014) · Pain Practice · doi:10.1111/papr.12127 · Cited by 65
Physiopathology of symptoms and signs in multiple sclerosis
Sá, M. J. (2012) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2012000900016 · Cited by 63
Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo
Mao, L., Liu, X., Zhang, G.-C., Chu, X., Fibuch, E. E., Wang, L. S., Liu, Z., & Wang, J. Q. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.034 · Cited by 63
Berk, Ç., Constantoyannis, C., & Honey, C. R. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100002626 · Cited by 63
Rehabilitation in multiple sclerosis.
Kubsik, A., Klimkiewicz, P., Klimkiewicz, R., et al. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/62329 · Cited by 61
Racke, M. K., Frohman, E. M., & Frohman, T. C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.799698 · Cited by 61
Demaneuf, T., Aitken, Z., Karahalios, A., Leong, T. I., Livera, A. M. D., Jelinek, G. A., Weiland, T. J., & Marck, C. H. (2018) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2018.08.178 · Cited by 60
Gerwin, R. D. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17197012 · Cited by 60
Medications for neuropathic pain: current trends
Colombo, B., Annovazzi, P. O. L., & Comı, G. (2006) · Neurological Sciences · doi:10.1007/s10072-006-0598-7 · Cited by 59
Prevalence of neuropathic pain in early multiple sclerosis
Heitmann, H., Biberacher, V., Tiemann, L., Buck, D., Loleit, V., Selter, R. C., Knier, B., Tölle, T. R., Mühlau, M., Berthele, A., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515613643 · Cited by 59
Alhaija, E. S. A., AlDaikki, A., AL-Omiri, M. K., et al. (2010) · The Angle Orthodontist · doi:10.2319/012710-59.1 · Cited by 58
Boiko, D. I., Chopra, H., Bilal, M., Kydon, P. V., Herasymenko, L. O., Rud, V. O., Боднарь, Л. А., Vasylyeva, G. Y., Isakov, R. І., Zhyvotovska, L. V., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.12.002 · Cited by 58
Self-citationThe Role of Psychologically Informed Physical Therapy for Musculoskeletal Pain
Archer, K. R., Coronado, R. A., & Wegener, S. T. (2018) · Current Physical Medicine and Rehabilitation Reports · doi:10.1007/s40141-018-0169-x · Cited by 57
Martin, S., Teo, M., & Suttner, N. J. (2015) · Journal of neurosurgery · doi:10.3171/2014.11.jns14736 · Cited by 56
The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey
Drulovic, J., Basic-Kes, V., Grgic, S., Vojinovic, S., Dincic, E., Toncev, G., Kezic, M. G., Kisic-Tepavcevic, D., Dujmovic, I., Mesaros, S., et al. (2015) · Pain Medicine · doi:10.1111/pme.12731 · Cited by 55
Systematic assessment and characterization of chronic pain in multiple sclerosis patients
Ferraro, D., Plantone, D., Morselli, F., Dallari, G., Simone, A. M., Vitetta, F., Sola, P., Primiano, G., Nociti, V., Pardini, M., et al. (2018) · Neurological Sciences · doi:10.1007/s10072-017-3217-x · Cited by 55
AMPA receptor trafficking in inflammation-induced dorsal horn central sensitization
Tao, Y.-X. (2012) · Neuroscience Bulletin · doi:10.1007/s12264-012-1204-z · Cited by 54
Transcranial magnetic stimulation (TMS) and repetitive TMS in multiple sclerosis
Aloizou, A., Pateraki, G., Anargyros, K., Siokas, V., Bakirtzis, C., Liampas, I., Νούσια, Α., Nasios, G., Sgantzos, M. N., Peristeri, E., et al. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0140 · Cited by 54
Kannan, P., Bello, U. M., & Winser, S. J. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221078672 · Cited by 54
Young, J., Zoghi, M., Khan, F., & Galea, M. P. (2020) · Pain Medicine · doi:10.1093/pm/pnaa128 · Cited by 52
Pain Management in Multiple Sclerosis: a Review of Available Treatment Options
Aboud, T., & Schuster, N. M. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0601-2 · Cited by 51
Systems and Circuits Linking Chronic Pain and Circadian Rhythms
Warfield, A. E., Prather, J. F., & Todd, W. D. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.705173 · Cited by 51
Abnormal Activity of Primary Somatosensory Cortex in Central Pain Syndrome
Quiton, R. L., Masri, R. M., Thompson, S. M., & Keller, A. (2010) · Journal of Neurophysiology · doi:10.1152/jn.00161.2010 · Cited by 50
Percutaneous glycerol rhizotomy for trigeminal neuralgia: safety and efficacy of repeat procedures
Harries, A. M., & Mitchell, R. D. (2011) · British Journal of Neurosurgery · doi:10.3109/02688697.2011.558946 · Cited by 50
Bender, M. T., Pradilla, G., Batra, S., See, A. P., James, C. S., Pardo, C. A., Carson, B. S., & Lim, M. K. (2012) · Journal of neurosurgery · doi:10.3171/2012.9.jns1226 · Cited by 49
Noorani, I., Lodge, A., Vajramani, G., & Sparrow, O. (2019) · Neurosurgery · doi:10.1093/neuros/nyz103 · Cited by 49
Treating pain in multiple sclerosis
Truini, A., Galeotti, F., & Cruccu, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.607162 · Cited by 48
Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models
Stamoula, Ε., Siafis, S., Dardalas, I., Ainatzoglou, A., Matsas, A., Athanasiadis, T., Sardeli, C., Stamoulas, K., & Papazisis, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677879 · Cited by 48
A randomized, placebo‐controlled trial of levetiracetam in central pain in multiple sclerosis
Falah, M., Madsen, C., Holbech, J. V., & Sindrup, S. H. (2012) · European Journal of Pain · doi:10.1002/j.1532-2149.2011.00073.x · Cited by 46
Continued uncertainty of TENS' effectiveness for pain relief
Johnson, M. I., & Walsh, D. M. J. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.77 · Cited by 45
Sawant, A., Dadurka, K., Overend, T. J., & Kremenchutzky, M. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.03.006 · Cited by 45
The pathology of multiple sclerosis: evidence for heterogeneity.
Morales, Y., Parisi, J. E., & Lucchinetti, C. F. (2006) · PubMed · Cited by 45
Heitmann, H., Haller, B., Tiemann, L., Mühlau, M., Berthele, A., Tölle, T. R., Salmen, A., Ambrosius, B., Bayas, A., Asseyer, S., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000001767 · Cited by 41
Hansen, J. S., Gustavsen, S., Roshanisefat, H., Kant, M., Biering‐Sørensen, F., Andersen, C. Y., Olsson, A., Chow, H. H., Asgari, N., Hansen, J. R., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081079 · Cited by 41
Italian consensus on treatment of spasticity in multiple sclerosis
Comı, G., Solari, A., Leocani, L., Centonze, D., Otero‐Romero, S., & the Italian Consensus Group on treatment of spasticity in multiple sclerosis (2019) · European Journal of Neurology · doi:10.1111/ene.14110 · Cited by 40
Cannabidiol to Improve Mobility in People with Multiple Sclerosis
Rudroff, T., & Sosnoff, J. J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00183 · Cited by 39
Berra, E., Bergamaschi, R., Icco, R. D., Dagna, C., Perrotta, A., Rovaris, M., Grasso, M. G., Anastasio, M. G., Pinardi, G., Martello, F., et al. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00031 · Cited by 39
Lhermitte′s Sign: The Current Status
Khare, S., & Seth, D. (2015) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.150622 · Cited by 38
Hong, T., Ding, Y., & Yao, P. (2020) · Biochemistry Research International · doi:10.1155/2020/3854284 · Cited by 38
OMICs Technologies for Natural Compounds-based Drug Development
Aborode, A. T., Awuah, W. A., Mikhailova, T., Rahman, T. A., Pavlock, S., Kundu, M., Yarlagadda, R., Pustake, M. V., Correia, I. F. S., Mehmood, Q., et al. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220726092034 · Cited by 38
Self-citationLamotrigine adjunctive therapy in painful phenomena in MS: Preliminary observations
Cianchetti, C., Zuddas, A., Randazzo, A. P., Perra, L., & Marrosu, M. G. (1999) · Neurology · doi:10.1212/wnl.53.2.433 · Cited by 36
An update on the pharmacological management of pain in patients with multiple sclerosis
Chisari, C. G., Sgarlata, E., Arena, S., D’Amico, E., Toscano, S., & Patti, F. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1757649 · Cited by 36
Frequency, type, distribution of pain and related factors in persons with multiple sclerosis,
Kahraman, T., Özdoğar, A. T., Ertekin, Ö., & Özakbaş, S. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.01.002 · Cited by 35
Cognitive Behavioral Therapy for the Management of Multiple Sclerosis–Related Pain
Gromisch, E. S., Kerns, R. D., Czlapinski, R., Beenken, B., Otis, J., Lo, A. C., & Beauvais, J. (2020) · International Journal of MS Care · doi:10.7224/1537-2073.2018-023 · Cited by 34 · cited 1×
“Therefore, both methods have potential for further use [179].”
Mirabelli, E., & Elkabes, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.793745 · Cited by 34
Emerging role of nanomedicine in the treatment of neuropathic pain
Bidve, P., Prajapati, N., Kalia, K., Tekade, R. K., & Tiwari, V. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1587444 · Cited by 30
Godazandeh, K., Sosa, S. M., Wu, J., & Zakrzewska, J. M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.06.015 · Cited by 30
Franzini, A., Tropeano, M. P., Olei, S., Robertis, M. D., Rossini, Z., Attuati, L., Milani, D., Pessina, F., Clerici, E., Navarria, P., et al. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.02.074 · Cited by 30
MRI of the central nervous system in MS patients with and without pain
Svendsenl, K. B., Sørensenl, L., Jensen, T. S., Hansenl, H. J., & Bach, F. W. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2010.09.006 · Cited by 29
Multiple Sclerosis-Related Pain Syndromes: An Imaging Update
Mazhari, A. (2016) · Current Pain and Headache Reports · doi:10.1007/s11916-016-0594-4 · Cited by 29
Provenzano, D. A., Williams, J. R., Jarzabek, G., DeRiggi, L. A., & Scott, T. F. M. (2016) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12409 · Cited by 26
Browne, T. J., Hughes, D. I., Dayas, C. V., Callister, R. J., & Graham, B. A. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.560802 · Cited by 26
Hadoush, H., Alawneh, A., Kassab, M. I., Al-Wardat, M. S., & Al-Jarrah, M. D. (2022) · Neurorehabilitation · doi:10.3233/nre-210328 · Cited by 26
Neurosurgical treatment of multiple sclerosis
Patwardhan, R. V., Minagar, A., Kelley, R. E., et al. (2006) · Neurological Research · doi:10.1179/016164106x98224 · Cited by 25
Sleep and armed conflict: future complications of war in Ukraine
Shkodina, A. D., Zhyvotovska, A. I., & Boiko, D. I. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.09.002 · Cited by 23
Self-citationDo changes in brain sodium channels cause central pain?
Max, M. B., & Hagen, N. A. (2000) · Neurology · doi:10.1212/wnl.54.3.544 · Cited by 22
Sadeghi-Bahmani, D., Esmaeili, L., Mokhtari, F., Sadeghi Bahmani, L., Afsharzadeh, M., Shaygannejad, V., Mirmosayyeb, O., Goldstein-Piekarski, A. N., & Gross, J. J. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104029 · Cited by 22 · cited 1×
“…ACT have a positive impact on the paresthesia experienced by patients with MS. Acceptance and commitment therapy and mindfulness-based stress reduction reduce pain perception over time, which may be explained by considering paresthesia as an indicator of cognitive-emotional pain processing [182].”
Texakalidis, P., Xenos, D., Karras, C. L., et al. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.11.006 · Cited by 21
MRI characteristics of periaqueductal lesions in multiple sclerosis
Papadopoulou, A., Naegelin, Y., Weier, K., Amann, M., Hirsch, J. G., von Felten, S., Yaldizli, Ö., Sprenger, T., Radue, E. W., Kappos, L., et al. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.01.001 · Cited by 20
Scope and Applications of Nanomedicines for the Management of Neuropathic Pain
Kuthati, Y., Rao, V. N., Busa, P., Tummala, S., Naga, G. D. V., & Wong, C. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01027 · Cited by 20
Spina, A., Nocera, G., Boari, N., et al. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01507-3 · Cited by 19
Dworsky-Fried, Z., Faig, C. A., Vogel, H. A., Kerr, B. J., & Taylor, A. M. W. (2021) · Pain · doi:10.1097/j.pain.0000000000002307 · Cited by 19
Nightly Sublingual Tizanidine HCl in Multiple Sclerosis
Vakhapova, V., Auriel, E., & Karni, A. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181daad7d · Cited by 17
Multiple Sclerosis and the Endogenous Opioid System
Dworsky-Fried, Z., Chadwick, C. I., Kerr, B. J., & Taylor, A. M. W. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.741503 · Cited by 17
Leduc, W., Mathieu, D., Adam, E., et al. (2023) · Neurosurgery · doi:10.1227/neu.0000000000002440 · Cited by 17
Sîrbu, C. A., Georgescu, R., Pleşa, C., Păunescu, A., Ţânţu, M. M., Nicolae, A. C., Caloianu, I., & Mitrică, M. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001568 · Cited by 17
Kırmacı, Z. İ. K., Adıgüzel, H., Göğremiş, M., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104541 · Cited by 15
Pain in patients with multiple sclerosis
Kasap, Z., & Uğurlu, H. (2022) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2022.10524 · Cited by 15
Harrison, A. M., McCracken, L. M., Jones, K., Norton, S., & Moss-Morris, R. (2017) · Disability and Rehabilitation · doi:10.1080/09638288.2016.1209580 · Cited by 14
Mousavi, S. H., Gehling, P., & Burchiel, K. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000001817 · Cited by 14
Pharmacotherapeutic Options for Managing Pain in Multiple Sclerosis
Stefano, G. D., Stefano, G. D., Lionardo, A. D., Cruccu, G., & Truini, A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00731-7 · Cited by 12
Chen, M. L., Yao, L., Boger, J. N., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016002 · Cited by 10
Recent advances in nanoplatforms for the treatment of neuropathic pain
Yu, B., Wu, K.-Z., Xu, X., Liu, Y., & Jiang, J. (2022) · Spinal Cord · doi:10.1038/s41393-021-00746-x · Cited by 10
Evidence Mapping Based on Systematic Reviews of Cognitive Behavioral Therapy for Neuropathic Pain
Li, C., Hou, W., Ding, D., Yang, Y., Gu, S., & Zhu, Y. (2023) · Neural Plasticity · doi:10.1155/2023/2680620 · Cited by 10
Foley, P., Parker, R. A., Angelis, F. D., Connick, P., Chandran, S., Young, C. A., Weir, C. J., & Chataway, J. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103925 · Cited by 9
Prescription opioid use in multiple sclerosis
Marrie, R. A., Fisk, J. D., Walld, R., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329508 · Cited by 9
Link, K. M., Knowles, L. M., Alschuler, K. N., & Ehde, D. M. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104742 · Cited by 9
Central Pain in Patients with Multiple sclerosis
S, F., I, W., P, V., & J, M. (2017) · Journal of Multiple Sclerosis · doi:10.4172/2376-0389.1000208 · Cited by 8 · cited 2×
“There are a few studies showing the prevalence of Lhermitte’s phenomenon in MS, with the incidence range from 9 to 41% [7, 11].”
Barim, B. A., Lemcke, L., Schwake, M., Schipmann, S., & Stummer, W. (2020) · Acta Neurochirurgica · doi:10.1007/s00701-020-04486-4 · Cited by 7
Lam, C. M., & Monroe, B. R. (2018) · A&A Practice · doi:10.1213/xaa.0000000000000918 · Cited by 6
Global research trends of nanotechnology for pain management
Zhu, Y., Yao, Y., Kuang, R., Chen, Z., Du, Z., & Qu, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1249667 · Cited by 6
A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis
Plantone, D., Vollono, C., Pardini, M., Primiano, G., Myftari, V., Vitetta, F., Sola, P., Massimiliano Mirabella, A., & Ferraro, D. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04745-3 · Cited by 5
Investigation of Neuropathic Pain Distribution and Related Factors in People with Multiple Sclerosis
Karakaş, H., Kaya, E., Abasıyanık, Z., & Özdoğar, A. T. (2022) · Journal of Multiple Sclerosis Research · doi:10.4274/jmsr.galenos.2022.2022-7-2 · Cited by 4
Delva, M. Y., Skoryk, K., & Delva, I. I. (2023) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v94i6.14609 · Cited by 4
Self-citationSerhan, A. O., Kiwan, A., Abushukair, H. M., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103491 · Cited by 1
Нефьодов О.О., К. А. И. (2022) · Український медичний часопис · doi:10.32471/umj.1680-3051.147.226789 · Cited by 1
Research works printed but not linked: 4
- Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44:S34–42 (discussion S42–3).
- Belousov AN, Belousova EY, Lekomtseva YV. Prospects for the application of nanotechnology in the treatment of multiple sclerosis. Int J Clin Med Case Rep. 2023;2:1–8. https://doi.org/10.31579/2834-8664/017. · doi:10.31579/2834-8664/017
- Boiko DI, Kachur RV, Ajala OM, Bodnar LA, Zhyvotovska LV. Characteristics of anxiety and depressive manifestations in patients with acute myocardial infarction taking into account their personal accentuations. Azerbaijan Med J. 2021;2:25–31. https://doi.org/10.34921/amj.2021.2.004. · doi:10.34921/amj.2021.2.004
- Hasanpour DA. Influence of yoga and aerobics exercise on fatigue, pain and psychosocial status in patients with multiple sclerosis: a randomized trial. J Sports Med Phys Fitness. 2016;56:1417–22.
Cited by
Chronic Stress and Autoimmunity: The Role of HPA Axis and Cortisol Dysregulation
Nunez, S. G., Rabelo, S. P., Subotic, N., Caruso, J. W., & Knezevic, N. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209994 · Cited by 138
“These findings are consistent with broader evidence supporting exercise-based therapies in autoimmune-related chronic pain conditions [93].”
Shaheen, K., Alam, A., Elhenawy, A. A., Khan, I. A., Rahman, F. U., Ali, A., Rehman, M. U., AlAsmari, A. F., Alasmari, F., Ahmad, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-13351-2 · Cited by 10
“Besides, compound 7 demonstrated some activity, with a 26.66% reduction in edema, while compounds 6 , 8 , and 4 showed minimal activity, with reductions of 13.33%, 10.00% and 3.33%, respectively.”
InfluentialNeuropathic pain in multiple sclerosis: serum biomarkers and MRI lesion localization
Ismail, M. H., ELmotayam, A. S., Saadawy, S. F., Elfwakhry, R. M., Fawzy, H. M., & Sarhan, N. T. (2025) · The Egyptian Journal of Neurology, Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00955-8 · Cited by 2
“Consequently, there is a demand for newer alternatives that are based on established pathophysiological mechanisms, which offer enhanced effectiveness and/or decreased side effects [29].”
Jungersen, R. C., Baccaro, V. K., Hvid, L. G., Dalgas, U., & Hoegh, M. (2026) · European Journal of Pain · doi:10.1002/ejp.70375 · Cited by 1
Metadata
- Authors
- Shkodina, A. D., Bardhan, M., Chopra, H., Anyagwa, O. E., Pinchuk, V. A., Hryn, K. V., Kryvchun, A. M., Boiko, D. I., Suresh, V., Verma, A., & Delva, M. Y.
- Affiliations
- Poltava State Medical University (UA)
- Baptist Hospital of Miami (US)
- Saveetha University (IN)
- New Vision University (GE)
- King George's Medical University (IN)
- Corresponding author
- Bardhan, Mainak
- ORCID
- Venue
- CNS Drugs
- Published
- 2024-02-29
- Volume
- 38
- Issue
- 3
- Pages
- 205-224
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W4392293990
- Cited by
- 31
- References
- 188
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 6
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Poltava State Medical University (0120U104165, 0121U108235)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- multiple sclerosis, neuropathic pain, trigeminal neuralgia, mixed pain, cannabinoids, muscle relaxants, antiepileptic drugs, antidepressants, opioids, botulinum toxin, non-pharmacological treatment, cognitive behavioral therapy, acceptance and commitment therapy, mindfulness-based stress reduction, physiotherapy, neurosurgery
- MeSH terms
- Anticonvulsants, Antidepressive Agents, Humans, Multiple Sclerosis, Neuralgia, Trigeminal Neuralgia, Acceptance and Commitment Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.